Therapeutic targets for schizophrenia

Drugs of the Future

Volumn 33, Issue 11, 2008, Pages 981-989

  D'Agostino, A ^a   Bozzo, J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; 5 [4 [5 (4 FLUOROPHENYL) 3 PYRIDINYLMETHYL] 1 PIPERAZINYL] 1,4 BENZODIOXAN; 8 [4 [3 (5 FLUORO 1H INDOL 3 YL)PROPYL] 1 PIPERAZINYL] 2 METHYL 1,4 BENZOXAZIN 3(4H) ONE; AMISULPRIDE; AMPA RECEPTOR AGONIST; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIFEPRUNOX; BLONANSERIN; CANNABINOID 1 RECEPTOR ANTAGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HISTAMINE H3 RECEPTOR ANTAGONIST; ILOPERIDONE; LURASIDONE; METABOTROPIC RECEPTOR AGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; NICOTINIC AGENT; NORCLOZAPINE; OLANZAPINE; PIMAVANSERIN; PROTEIN KINASE C INHIBITOR; QUETIAPINE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TACHYKININ RECEPTOR ANTAGONIST; UNINDEXED DRUG; ZIPRASIDONE;

ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; COMMUNITY REINTEGRATION; DEPRESSION; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MENTAL DISEASE; MOOD DISORDER; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PATHOPHYSIOLOGY; PSYCHOSOCIAL CARE; SCHIZOPHRENIA;

EID: 60549100510     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.011.1282565     Document Type: Article

References (48)

1. Rowley, M., Bristow, L.J., Hutson, P.H. Current and novel approaches to the drug treatment of schizophrenia. J Med Chem 2001, 44(4): 477-501.
2. Schultz, S.H., North, S.W., Shields, C.G. Schizophrenia: A review. Am Fam Physician (1970) 2007, 75(12): 1821-9.
3. Freedman, R. Schizophrenia. New Engl J Med 2003, 349(18): 1738-49.
4. Lewis, D.A., Gonzalez-Burgos, G. Pathophysiologically based treatment interventions in schizophrenia. Nat Med 2006, 12(9): 1016-22.
5. Stroup, T.S., Alves, W.M., Hamer, R.M., Lieberman, J.A. Clinical trials for antipsychotic drugs: Design conventions, dilemmas and innovations. Nat Rev Drug Discov 2006, 5(2): 133-46.
6. 1A receptor agonist potential antipsychotic drug. Neuropsychopharmacology 2007, 32(1): 78-94.
7. Sorbera, L.A., Castañer, T. Bifeprunox mesilate. Drugs Fut 2005, 30(10): 992-7.
8. Yasuno, F., Suhara, T., Ichimiya, T., Takano, A., Ando, T., Okubo, Y. Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol Psychiatry 2004, 55(5): 439-44.
9. Arranz, B., Rosel, P., Ramírez, N., San, L. Genetic dysfunction of the serotonin receptor 5-HT2A in psychiatric disorders. Actas Esp Psiquiatr 2001, 29(2): 131-8.
10. Meltzer, H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999, 21(2, Suppl.): 106S-15S.
11. Puig, M.V., Celada, P., Artigas, F. Serotonergic control of prefrontal cortex. Rev Neurol 2004, 39(6): 539-47.
12. González-Maeso, J., Ang, R.L., Yuen, T. et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008, 452(7183): 93-7.
13. Wacker, D.A., Miller, K.J. Agonists of the serotonin 5-HT2C receptor: Preclinical and clinical progression in multiple diseases. Curr Opin Drug Discov Devel 2008, 11(4): 438-45.
14. Passani, M.B., Blandina, P. Cognitive implications for H3 and 5-HT3 receptor modulation of cortical cholinergic function: A parallel story. Meth Find Exp Clin Pharmacol 1998, 20(8): 725-33.
15. Adler, L.E., Cawthra, E.M., Donovan, K.A., Harris, J.G., Nagamoto, H.T., Olincy, A., Waldo, M.C. Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. Am J Psychiatry 2005, 162(2): 386-8.
16. Nagayama, T., Sinor, A.D., Simon, R.P., Chen, J., Graham, S.H., Jin, K., Greenberg, D.A. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999, 19(8): 2987-95.
17. Freedman, R. Cannabis, inhibitory neurons, and the progressive course of schizophrenia. Am J Psychiatry 2008, 165(4): 416-9.
18. Wang, M., Lee, F.J., Liu, F. Dopamine receptor interacting proteins (DRIPs) of dopamine D1-like receptors in the central nervous system. Mol Cells 2008, 25(2): 149-57.
19. Frånberg, O., Wiker, C., Marcus, M.M. et al. Asenapine, a novel psychopharmacologic agent: Preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) 2008, 196(3): 417-29.
20. Uzun, S., Kozumplik, O., Mimica, N., Folnegovic-Smalc, V. Aripiprazole: An overview of a novel antipsychotic. Psychiatr Danub 2005, 17(1-2): 67-75.
21. Micheli, F., Heidbreder, C. Selective dopamine D3 receptor antagonists: A review 2001-2005. Recent Patents CNS Drug Discov 2006, 1(3): 271-88.
22. Lewis, D.A., Volk, D.W., Hashimoto, T. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: A novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl) 2004, 174(1): 143-50.
23. Nudelman, A., Gil-Ad, I., Shpaisman, N. A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects. J Med Chem 2008, 51(9): 2858-62.
24. Hashimoto, K. Glycine transporter inhibitors as therapeutic agents for schizophrenia. Recent Patents CNS Drug Discov 2006, 1(1): 43-53.
25. Lim, R., Hoang, P., Berger, A.J. Blockade of glycine transporter-1 (GlyT-1) potentiates NMDA receptor-mediated synaptic transmission in hypoglossal motor neurons. J Neurophysiol 2004, 92(4): 2530-7.
26. Bongers, G., Bakker, R.A., Leurs, R. Molecular aspects of the histamine H3 receptor. Biochem Pharmacol 2007, 73(8): 1195-204.
27. Passani, M.B., Lin, J.S., Hancock, A., Crochet, S., Blandina, P. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 2004, 25(12): 618-25.
28. Ligneau, X., Landais, L., Perrin, D. Brain histamine and schizophrenia: Potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Biochem Pharmacol 2007, 73(8): 1215-24.
29. Javitt, D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004, 9(11): 984-97.
30. Wezenberg, E., Verkes, R.J., Ruigt, G.S., Hulstijn, W., Sabbe, B.G. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology 2007, 32(6): 1272-83.
31. Garofalo, P., Colombo, S., Lanza, M., Revel, L., Makovec, F. CR 2249: A new putative memory enhancer. Behavioural studies on learning and memory in rats and mice. J Pharm Pharmacol 1996, 48(12): 1290-7.
32. Lanza, M., Bonnafous, C., Colombo, S., Revel, L., Makovec, F. Characterization of a novel putative cognition enhancer mediating facilitation of glycine effect on strychnine-resistant sites coupled to NMDA receptor complex. Neuropharmacology 1997, 36(8): 1057-64.
33. Endoh, T. Characterization of modulatory effects of postsynaptic metabotropic glutamate receptors on calcium currents in rat nucleus tractus solitarius. Brain Res 2004, 1024(1-2): 212-24.
34. Woolley, M.L., Pemberton, D.J., Bate, S., Corti, C., Jones, D.N. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl) 2008, 196(3): 431-40.
35. Patil, S.T., Zhang, L., Martenyi, F. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial. Nat Med 2007, 13(9): 1102-7.
36. Harrison, P.J., Lyon, L., Sartorius, L.J., Burnet, P.W., Lane, T.A. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): Expression, function and involvement in schizophrenia. J Psychopharmacol 2008, 22(3): 308-22.
37. Chavez-Noriega, L.E., Schaffhauser, H., Campbell, U.C. Metabotropic glutamate receptors: Potential drug targets for the treatment of schizophrenia. Curr Drug Targets CNS Neurol Disord 2002, 1(3): 261-81.
38. Clader, J.W., Wang, Y.G. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease. Curr Pharm Des 2005, 11(26): 3353-61.
39. Han, M., Newell, K., Zavitsanou, K., Deng, C., Huang, X.F. Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. J Neurosci Res 2008, 86(2): 457-64.
40. Broad, L.M., Sher, E., Astles, P.C., Zwart, R., O'Neill, M.J. Selective α7 nicotinic acetylcholine receptor ligands for the treatment of neuropsychiatric diseases. Drugs Fut 2007, 32(2): 161-70.
41. Olincy, A., Harris, J.G., Johnson, L.L. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006, 63(6): 630-8.
42. Jayanthi, L.D., Ramamoorthy, S. Regulation of monoamine transporters: Influence of psychostimulants and therapeutic antidepressants. AAPS J 2005, 7(3): E728-38.
43. Friedman, J.I., Carpenter, D., Lu, J. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol 2008, 28(1): 59-63.
44. Carter, C.A. Protein kinase C as a drug target: Implications for drug or diet prevention and treatment of cancer. Curr Drug Targets 2000, 1(2): 163-83.
45. Cho, E.Y., Cho, D.I., Park, J.H., Kurose, H., Caron, M.G., Kim, K.M. Roles of protein kinase C and actin-binding protein 280 in the regulation of intracellular trafficking of dopamine D3 receptor. Mol Endocrinol 2007, 21(9): 2242-54.
46. Rao, H., Gillihan, S.J., Wang, J. Genetic variation in serotonin transporter alters resting brain function in healthy individuals. Biol Psychiatry 2007, 62(6): 600-6.
47. Smith, P.W., Dawson, L.A. Neurokinin 3 (NK3) receptor modulators for the treatment of psychiatric disorders. Recent Patents CNS Drug Discov 2008, 3(1): 1-15.
48. Chahl, LA. Tachykinins and neuropsychiatric disorders. Curr Drug Targets 2006, 7(8): 993-1003.